Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.
13d
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback